Miltefosine and emerging Leishmania (Mundinia) in Southeast Asia: Molecular insights, therapeutic challenges, and future strategic implementation
{{output}}
Miltefosine, the only oral antileishmanial drug with regulatory approval, has expanded treatment options in several endemic settings but shows variable efficacy across Leishmania species, clinical forms, and host immune contexts. In Southeast Asia, where Leish... ...
